Arvinas Financials

ARVN Stock  USD 12.20  1.03  9.22%   
Based on the key indicators related to Arvinas' liquidity, profitability, solvency, and operating efficiency, Arvinas may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At this time, Arvinas' Other Stockholder Equity is very stable compared to the past year. As of the 7th of January 2026, Property Plant And Equipment Gross is likely to grow to about 50.2 M, while Total Assets are likely to drop about 802.9 M. Key indicators impacting Arvinas' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Debt Equity Ratio0.01890.0199
Notably Down
Very volatile
Current Ratio7.195.34
Significantly Up
Slightly volatile
Investors should never underestimate Arvinas' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Arvinas' cash flow, debt, and profitability to make informed and accurate decisions about investing in Arvinas.

Net Income

(187.96 Million)

  
Build AI portfolio with Arvinas Stock
Understanding current and past Arvinas Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Arvinas' financial statements are interrelated, with each one affecting the others. For example, an increase in Arvinas' assets may result in an increase in income on the income statement.

Arvinas Stock Summary

Arvinas competes with Valneva SE, ArriVent BioPharma, Day One, Astria Therapeutics, and Replimune. Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut. Arvinas operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 280 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS04335A1051
Business Address5 Science Park,
SectorPharmaceuticals
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.arvinas.com
Phone203 535 1456
CurrencyUSD - US Dollar

Arvinas Key Financial Ratios

Arvinas Key Balance Sheet Accounts

202120222023202420252026 (projected)
Total Assets1.6B1.3B1.3B1.1B1.3B802.9M
Other Current Liab23.1M58.7M73.7M55.2M63.5M66.7M
Other Liab38.4M22.9M534.3M405.1M465.9M489.2M
Net Tangible Assets226.7M642.3M781.7M564.9M649.6M354.8M
Net Debt(103.3M)(75.8M)(308.5M)(90.8M)(81.7M)(85.8M)
Retained Earnings(682.9M)(965.4M)(1.3B)(1.5B)(1.4B)(1.3B)
Accounts Payable31.3M5.7M17.8M13.4M15.4M10.4M
Cash108.3M81.3M311.7M100.5M115.6M151.4M
Other Assets28.8K100K10.8M1.01.151.09
Net Receivables25.7M8M7.2M13.7M15.8M12.4M
Other Current Assets24.2M26.9M12M14.2M16.3M11.1M
Total Liab799.9M703.9M644.6M529.7M609.2M363.2M
Total Current Assets1.6B1.2B1.3B1.1B1.2B786.2M
Short Term Debt1M1.1M1.8M1.9M2.1M1.1M
Net Invested Capital782.7M565.9M660.8M562.3M646.6M484.3M
Net Working Capital1.3B945.1M1.0B837.5M963.1M719.0M
Capital Surpluse599.1M1.1B1.5B1.5B1.8B1.1B

Arvinas Key Income Statement Accounts

202120222023202420252026 (projected)
Net Interest Income1.8M12.2M32.3M54.8M63.0M66.2M
Interest Income1.9M12.2M32.3M54.8M63.0M66.2M
Interest Expense85.6K65K100K12M13.8M14.5M
Total Revenue46.7M131.4M78.5M263.4M302.9M318.1M
Gross Profit46.7M131.4M78.5M263.4M302.9M318.1M
Operating Income(195.3M)(263.2M)(401.5M)(250.2M)(225.2M)(236.4M)
Ebit(195.3M)(263.2M)(401.5M)(250.2M)(225.2M)(236.4M)
Research Development180.4M315M379.7M348.2M400.4M420.5M
Ebitda(189.3M)(255M)(394.8M)(243.6M)(219.2M)(230.2M)
Income Before Tax(191M)(251M)(366.4M)(198.3M)(178.5M)(187.4M)
Net Income(183.2M)(271.9M)(367.3M)(198.9M)(179.0M)(188.0M)
Income Tax Expense(7.8M)20.9M900K600K690K724.5K

Arvinas Key Cash Accounts

202120222023202420252026 (projected)
Investments(1.3B)249.6M276.6M34.7M39.9M41.9M
Change In Cash(475.6M)(26M)230.4M(216.7M)(195.0M)(185.3M)
Free Cash Flow554.7M(280.3M)(350.7M)(261.1M)(235.0M)(223.2M)
Depreciation6M8.2M6.7M6.6M7.6M4.3M
Other Non Cash Items9M7.9M(14.4M)(14.6M)(13.1M)(12.5M)
Capital Expenditures4.7M6.8M2.9M1.8M2.1M4.0M
Net Income(191M)(282.5M)(367.3M)(198.9M)(179.0M)(188.0M)
End Period Cash Flow112.8M86.8M317.2M100.5M115.6M153.3M
Change To Netincome20.1M29.8M65.7M75.5M86.8M91.2M
Change Receivables(1.2M)(2.2M)(17.3M)17.7M15.9M16.7M

Arvinas Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Arvinas's current stock value. Our valuation model uses many indicators to compare Arvinas value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Arvinas competition to find correlations between indicators driving Arvinas's intrinsic value. More Info.
Arvinas is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . At this time, Arvinas' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Arvinas' earnings, one of the primary drivers of an investment's value.

Arvinas Systematic Risk

Arvinas' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Arvinas volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Arvinas correlated with the market. If Beta is less than 0 Arvinas generally moves in the opposite direction as compared to the market. If Arvinas Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Arvinas is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Arvinas is generally in the same direction as the market. If Beta > 1 Arvinas moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Arvinas Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Arvinas' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Arvinas growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.14

At this time, Arvinas' Price Earnings To Growth Ratio is very stable compared to the past year.

Arvinas January 7, 2026 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Arvinas help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Arvinas. We use our internally-developed statistical techniques to arrive at the intrinsic value of Arvinas based on widely used predictive technical indicators. In general, we focus on analyzing Arvinas Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Arvinas's daily price indicators and compare them against related drivers.
When determining whether Arvinas offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Arvinas' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Arvinas Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Arvinas Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arvinas. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services.
To learn how to invest in Arvinas Stock, please use our How to Invest in Arvinas guide.
You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arvinas. If investors know Arvinas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arvinas listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.81)
Revenue Per Share
4.299
Quarterly Revenue Growth
(0.59)
Return On Assets
(0.06)
Return On Equity
(0.10)
The market value of Arvinas is measured differently than its book value, which is the value of Arvinas that is recorded on the company's balance sheet. Investors also form their own opinion of Arvinas' value that differs from its market value or its book value, called intrinsic value, which is Arvinas' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arvinas' market value can be influenced by many factors that don't directly affect Arvinas' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arvinas' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arvinas is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arvinas' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.